Key result
Impaired renal function is linked to higher mortality and HF hospitalization regardless of LVEF.
Why the study?
Does impaired renal function predict adverse outcomes in patients with heart failure, and does baseline eGFR modify the beneficial effect of candesartan?
Does impaired renal function predict adverse outcomes in patients with heart failure, and does baseline eGFR modify the beneficial effect of candesartan?
Impaired renal function is a strong independent predictor of adverse outcomes in heart failure across the LVEF spectrum, but does not diminish the therapeutic benefit of candesartan.
Answers are grounded in this paper and cite their sources.
Renal impairment aids HF risk stratification across LVEF; leaves open whether eGFR should guide candesartan use in prospective trials.
Impaired renal function is independently associated with heightened risk for death, cardiovascular death, and hospitalization for heart failure in patients with CHF with both preserved as well as reduced LVEF. There was no evidence that the beneficial effect of candesartan was modified by baseline eGFR.
No takes yet. Share an insight, caveat, or question.
Hillege et al. (2006) studied this question. Impaired renal function is independently associated with a higher risk of mortality and heart failure hospitalization regardless of LVEF, without modifying the benefit of candesartan.
Synapse has enriched 10 related papers. Consider them for comparative context: